A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms ANGEL
- Sponsors LSK Biopharma
- 20 Dec 2017 According to a LSK Biopharma media release, 1/3 of total expected patients have been enrolled in this trial. This was designed with input from the US FDA, the PMDA (Japan), EMA (EU), TFDA (Taiwan), and MFDS (South Korea).
- 20 Dec 2017 According to a LSK Biopharma media release, the first US and European patients have been enrolled in this trial.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.